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Circadian rhythms are endogenous cycles with periods close to, but not exactly equal to, 24 h. In
mammals, circadian rhythms are generated in the suprachiasmatic nucleus (SCN) of the
hypothalamus as well as several peripheral cell types, such as fibroblasts. Protein kinases are key
regulators of the circadian molecular machinery. We investigated the role of the c-Jun N-terminal
kinases (JNK), which belong to the mitogen-activated protein kinases family, in the regulation of
circadian rhythms. In rat-1 fibroblasts, the p46 kDa, but not the p54 kDa, isoforms of JNK expressed
circadian rhythms in phosphorylation. The JNK-inhibitor SP600125 dose-dependently extended the
period of Period1-luciferase rhythms in rat-1 fibroblasts from 24.23±0.17–31.48±0.07 h. This
treatment also dose-dependently delayed the onset of the bioluminescence rhythms. The effects of
SP600125 on explant cultures from Period1-luciferase transgenic mice and Period2Luciferase knockin
mice appeared tissue-specific. SP600125 lengthened the period in SCN, pineal gland, and lung
explants in Period1-luciferase and Period2Luciferase mice. However, in the kidneys circadian rhythms
were abolished in Period1-luciferase, while circadian rhythms were not affected by SP600125
treatment in Period2Luciferase mice. Valproic acid, already known to affect period length, enhanced
JNK phosphorylation and, as predicted, shortened the period of the Period1-bioluminescence
rhythms in rat-1 fibroblasts. In conclusion, our results showed that SP600125 treatment, as well as
valproic acid, alters JNK phosphorylation levels, and modulates the period length in various tissues.
We conclude that JNK phosphorylation levels may help to set the period length of mammalian
circadian rhythms.
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Developed through evolution to adjust to environmental conditions, self-sustained circadian
oscillators generate daily fluctuations in behavior and physiology with a period of
approximately 24 h. The study of the mammalian circadian clock at molecular levels has
progressed dramatically over the past decade (Fukuhara and Tosini, 2003; Schibler et al.,
2003; Gachon et al., 2004). In mammals, the central circadian clock is localized to the
suprachiasmatic nucleus (SCN) of the hypothalamus, which synchronizes circadian events
within the body. Peripheral circadian clocks have been found in many types of cells and tissues,
e.g. fibroblasts, pineal gland, heart, liver, kidney, lung, and so on. Sustained circadian rhythm
can be generated not only in a SCN neuron, but also in a fibroblast and other tissues and organs.
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Furthermore, expression patterns of circadian clock genes and proteins are similarly observed
between the SCN neurons and peripheral cells, tissues and organs (Ko and Takahashi, 2006).
These observations suggest that circadian machinery is likely the same or similar between the
central and peripheral cells. Therefore, the findings enable us to use peripheral cells and organs
to study machinery of circadian rhythm generation.
Numerous studies of the molecular clock mechanism have suggested that these circadian
pacemakers consist of transcriptional/translational autoregulatory feedback loops of several
clock gene products (Hastings and Herzog, 2004; Ko and Takahashi, 2006). The stability of
clock proteins, regulated through phosphorylation and dephosphorylation via protein kinases
and phosphatases, is now recognized as a critical component to properly regulate the period of
circadian oscillations. In the Syrian hamster, the tau mutation located in the locus of the casein
kinase Iε (CKIε) gene (Lowrey et al., 2000), modifies PERIOD protein phosphorylation
(Gallego et al., 2006) and shortens the period of the behavioral locomotor activity rhythms
(Ralph and Menaker, 1988).
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The mitogen-activated protein kinases (MAPK), members of the superfamily of serine/
threonine kinases, are intracellular signal transduction enzymes that respond to a wide range
of external stimuli such as mechanical stimulation, growth factors, hormones, or cytokines.
They play an essential role in regulating several intracellular processes, such as gene
expression, growth, cell survival, differentiation or death (Barr and Bogoyevitch, 2001;
Pearson et al., 2001). To date, four main subfamilies have been identified: extracellularregulated kinases (ERK), p38MAPK, c-Jun N-terminal kinases (JNK) and big MAPK (BMK/
ERK5) (Pearson et al., 2001). The role of JNK in the regulation of the circadian molecular
machinery is of particular interest since JNK are involved in numerous illnesses such as
neurodegenerative diseases, cancers, and stroke (Bozyczko-Coyne et al., 2002; Manning and
Davis, 2003; Peng and Andersen, 2003; Resnick and Fennell, 2004), in which disturbed
circadian organization has been reported (Mormont and Levi, 1997; Garcia-Borreguero et al.,
2003; Onen and Onen, 2003; Walters et al., 2003; Morton et al., 2005).
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In the present study, we investigated what role JNK might play in the regulation of the
molecular clockwork in rat-1 fibroblasts using a JNK inhibitor SP600125. Since SP600125
affected period of circadian rhythm expression, we further studied the effects of the
anticonvulsant valproic acid, which has been used to treat bipolar disorder patients and is
known to affect period (Rietveld and van Schravendijk, 1987; Klemfuss and Kripke, 1995;
Dokucu et al., 2005), on JNK phosphorylation levels. By means of a real-time bioluminescence
monitoring apparatus, we monitored the effects of the chemicals on the expression patterns of
Period1-bioluminescence rhythms in rat-1 fibroblasts, and the effects of SP600125 on
Period1- and Period2-bioluminescence rhythms in central and peripheral tissues using
Period1-luciferase transgenic mice and Period2Luciferase knockin mice.

EXPERIMENTAL PROCEDURES
Animals
Transgenic mice carrying a Period1-luciferase transgene as a reporter of activity were
generously provided by Dr. Hajime Tei (Mitsubishi Kagaku Institute of Life Sciences, Tokyo,
Japan), and Period2Luciferase knockin mice harboring a luciferase reporter were obtained from
Dr. Joseph S. Takahashi (Northwestern University, Evanston, IL, USA) (Yamazaki et al.,
2000; Herzog et al., 2004; Yoo et al., 2004). Period1-luciferase and Period2Luciferase mice
were maintained at Morehouse School of Medicine and at Smith College, respectively. All
animals were housed under a 12-h light/dark cycle (lights on, 07:00–19:00 h) in a temperaturecontrolled environment and had access to food and water ad libitum. Zeitgeber time (ZT) 0
was defined as light onset and ZT 12 as lights off. Both heterozygous and homozygous mice
Neuroscience. Author manuscript; available in PMC 2008 March 30.

Chansard et al.

Page 3

NIH-PA Author Manuscript

were used in our experiments. All experiments were run under the oversight of IACUC of the
Atlanta University Center and the Smith College IACUC and NIH guidelines. The minimum
number of animals necessary to obtain a significant signal/noise ratio was used. The animals
were decapitated under anesthesia to minimize their suffering.
Cell and tissue cultures
Three days before starting experiments, 106 rat-1 fibroblasts, stably transfected with the
Period1-luciferase reporter gene (Izumo et al., 2003) (generous gift from Carl H. Johnson,
Vanderbilt University, Nashville, TN, USA), were seeded in 35 mm Petri dishes. Cells were
cultured at 36 °C under 5% CO2–95% air atmosphere in 2 mL of Dulbecco’s Eagle Modified
Medium (Gibco, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum (Gibco), 100
units/mL penicillin and 100 μg/mL streptomycin (Gibco). For all experiments, circadian
rhythms were synchronized among the cells by replacing the culture medium with 2 mL of
assay medium (Hirota et al., 2002), consisting of serum-free DMEM (Cellgro, Herndon, VA,
USA), 10 mM Hepes (Gibco), 350 mg/mL sodium bicarbonate (Gibco), 2% B27 Supplement
(Gibco), 25 units/mL penicillin, and 25 μg/mL streptomycin. For bioluminescence analysis,
0.1 mM luciferin (Promega, Madison, WI, USA) was added to the assay medium.
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For explant cultures, brain, pineal gland, lungs, and kidneys were quickly removed from
transgenic/knockin mice decapitated following overdose halothane anesthesia at ZT 11
(Yoshikawa et al., 2005), and were placed in cold Hanks’ Balanced Salt Solution (HBSS,
Invitrogen, Carlsbad, CA, USA). Brain coronal sections at 300-μm thickness were obtained
using a vibratome (World Precision Instruments, Sarasota, FL, USA). The brain section
containing the SCN was further dissected as 1×1 mm square. Lungs and kidneys were dissected
into pieces as ≈1 mm3 in volume. Each piece of lung and kidney was cultured individually in
a 35 mm Petri dish and SCN slices and the pineal gland were cultured on Millicell culture
membranes (Millipore, Billerica, MA, USA) placed in 35 mm dishes, sealed with silicon grease
and a circular glass coverslip.
For both fibroblasts and tissue explant cultures, SP600125 (1,9-pyrazoloanthrone, Calbiochem,
San Diego, CA, USA), JNK inhibitor negative control (N1-methyl-1,9-pyrazoloanthrone,
Calbiochem), vehicle or valproic acid (Sigma, St. Louis, MO, USA) was added at the beginning
of the record in the assay medium.
Cell survival assay
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Fibroblast preparations were obtained as described previously. The cells were cultured for 3
days in the presence or absence of 30 μM SP600125 or vehicle. Cells were then trypsinized
and incubated with 4% Trypan Blue dye for 5 min at room temperature. Fibroblasts were
examined under an inverted microscope using a hematocytometer and cell survival was
expressed in percentage, as the ratio of living cells on total number of cells.
Western blot analysis
Detailed procedures have been described in a previous study (Chansard et al., 2005). In brief,
protein extracts (30 μg) were separated on a SDS-PAGE gel and further transferred to a
nitrocellulose membrane. Each blot was successively incubated with primary antibodies
recognizing phosphorylated forms of JNK at Thr183 and Tyr185 (Cell Signaling Technology,
Danvers, MA, USA), total JNK (Cell Signaling Technology), and ACTIN (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The intensity of each band was measured using the
NIH ImageJ analysis software and was normalized toward the corresponding ACTIN band
intensity.

Neuroscience. Author manuscript; available in PMC 2008 March 30.
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Detailed procedures for bioluminescence monitoring and data analysis have been described
elsewhere (Yamazaki et al., 2000; Izumo et al., 2003). Bioluminescence rhythms were recorded
in a real-time bioluminescence monitoring system (Lumicycle, Actimetrics, Wilmette, IL,
USA). Petri dishes to be assayed were placed in a light-tight chamber placed in a 36 °C air
incubator. Photons emitted from cells in each Petri dish were monitored by photomultipliers
for 60 s at 10-min intervals. The data were acquired using a PCI-6601 card and a NI-DAQ 7.1
acquisition driver (National Instruments, Austin, TX, USA) associated with an acquisition
software (Lumicycle Software, Actimetrics).
Data analyses were performed using the Lumicycle Data Analysis Software (Actimetrics). The
raw data were subjected to baseline correction, performed by fitting a polynomial curve to the
data. The baseline fit curve obtained was subtracted from the raw data and the resulting
baseline-subtracted data were used to determine the period. A chi-square periodogram analysis
was performed on all baseline-subtracted data to establish whether or not there was a significant
circadian rhythm (Sokolove and Bushell, 1978). In this study, all the circadian rhythms
recorded from fibroblasts and tissues, except for some of the SP600125-treated Period1luciferase and Period2Luciferase mice kidneys, showed sig-nificant circadian rhythms (P<0.05).
The estimated period was obtained from a Fourier transform of the records: the software fits
the data to a sine wave multiplied by an exponential decay:
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L = A sin (2π / P − t0) × e−t/day

where L is the bioluminescence in counts/s, i.e. the photon counts emitted per second as
represented in the corresponding figures, P is the period in hours, t0 is the phase in cycles
relative to the start of the fitted portion of the data, A is the amplitude in counts/s and d is the
exponential damping time constant in days. The time points of the peaks and troughs of the
baseline-subtracted data are fitted to the dominant sine wave and then fitted to an exponential
decay. The damping rate was defined as the number of days necessary for the amplitude of the
rhythm to decrease to 1/e (≈36.79%) of its initial value.
The baseline level of bioluminescence, which corresponds to the background level, was
evaluated at 28.79±7.66 counts/s.
Statistics
Data are expressed as means±S.E.M. and statistical analysis was performed using parametric
and non-parametric statistics (ANOVA, Student’s t-test).
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RESULTS
Phosphorylation patterns of p46 kDa and p54 kDa JNK isoforms in rat-1 fibroblasts
First, the profiles of JNK phosphorylation throughout 24 h in rat-1 Period1-luciferase
fibroblasts were analyzed. The experiment was designed according to preliminary data, which
assessed the Period1-driven bioluminescence rhythms in Period1-luciferase rat-1 fibroblasts
after medium change, so that the samples were taken on a full circadian cycle (Fig. 1). Over
24 h, p46 kDa isoforms showed a rhythmic phosphorylation (Fig. 1A, ANOVA, P<0.05). The
peak of p46 kDa isoforms phosphorylation occurred 44 h after medium change (P<0.05 as
compared with the 36 h time point). As compared with the Period1-luciferase bioluminescence
rhythm, which reached its peak 28 h following synchronization, p46 kDa phosphorylation
peaked 16 h later, as assessed by the record of the Period1-driven bioluminescence oscillations
on the same time duration. p54 kDa did not display any significant fluctuations (Fig. 1B,
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ANOVA, P>0.1). Total amount of p46 kDa and p54 kDa isoforms remained unchanged over
the 24-h period (ANOVA, both cases, P>0.1).
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The effects of the JNK inhibitor SP600125 on the period of Period1-luciferase rhythms in rat-1
fibroblasts
To investigate whether JNK phosphorylation is required to maintain normal circadian
oscillations, the JNK specific inhibitor SP600125 was used. As compared with the control
condition, the period length was significantly extended in the presence of 30 μM SP600125
(P<0.0005, Table 1, Fig. 2). The amplitude of the oscillations was not affected by the SP600125
treatment (P>0.1, Table 1). Similarly, the damping rate was not significantly affected by the
SP600125 treatment (P>0.1, Table 1). Culturing cells in the presence of the SP600125 for 3
days did not affect the cell survival rate (control, 78.90±2.83%; SP600125, 75.93±0.43%).
To determine whether the vehicle by itself affected the period length of the Period1-driven
bioluminescence rhythm, we treated fibroblasts with dimethyl sulfoxide (DMSO). Oscillations
showed a period, which was not significantly different from the control condition (P>0.1, Table
1, Fig. 2). Although amplitude was significantly increased (P<0.05, Table 1), the damping rate
was unchanged (P>0.1, Table 1). DMSO did not affect the cell survival rate (81.60±2.19%,
P>0.1).
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Then, the effect of a JNK inhibitor negative control (30 μM) was tested. The period was not
affected by the negative control (P<0.1, Table 1, Fig. 2). Similarly, both amplitude and damping
rate stayed unchanged (both cases, P>0.1, Table 1).
The effects of SP600125 on phosphorylated JNK levels
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The acute and chronic effects of SP600125 treatment on the phosphorylation levels of p46 kDa
and p54 kDa isoforms were further analyzed. Both p46 kDa and p54 kDa isoforms were highly
and significantly phosphorylated 20 min after medium change (both cases, P<0.0005, Fig. 3A).
SP600125 prevented this acute phosphorylation (p46 kDa, P>0.1, p54 kDa, P>0.1). Total JNK
levels of p46 kDa and p54 kDa were not significantly affected 20 min after medium change
with or without SP600125 (P>0.05 in all cases). The effect of a chronic application of
SP600125 by harvesting the cells on a full circadian cycle was determined. Based on circadian
expression patterns of Period1-bioluminescence rhythms (Fig. 2), we decided to harvest cells
every 5 h for 30 h starting 30 h after medium change. As compared with the control condition
(Fig. 1), rhythmic p46 kDa phosphorylation was abolished by the SP600125 and
phosphorylation levels were low (Fig. 3B, ANOVA, P>0.1). As expected from the control
condition (Fig. 1), p54 kDa phosphorylation remained arrhythmic after SP600125 treatment
(ANOVA, P>0.1). The total levels of the two isoforms were not affected by the SP600125
treatments (both cases, ANOVA, P>0.1).
Characteristics of SP600125 in the regulation of the Period1-bioluminescence rhythms
Described in the literature as a reversible inhibitor (Bennett et al., 2001), we tested whether
the effect of SP600125 on the period length was reversible or not. We monitored oscillations
in bioluminescence levels for 3 days in the presence of 30 μM SP600125 before refreshing the
preparation with fresh medium without the inhibitor. After the medium change, the period was
then significantly shortened (before washout, 30.73±0.16 h; after washout, 24.44±0.10 h,
P<0.0005, Fig. 4A), which was not significantly different from the control condition, or that
from the vehicle condition (both cases, P>0.1).
We further found that SP600125 dose-dependently extended the period of the bioluminescence
rhythms (Fig. 4B); period was lengthened from 24.23±0.17 h (control, 0 μM) to 24.78±0.06 h
(3 μM, P<0.05), 27.07±0.09 h (10 μM, P<0.0005), 31.48±0.06 h (30 μM, P<0.0005) and 36.04
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±0.30 h (50 μM, P<0.0005). Moreover, the effect of 3 μM SP600125 was significantly different
from the effect of 10 μM inhibitor (P<0.05). Similarly, the effect of 10 μM SP600125 was
significantly different from 30 μM (P<0.0005), and 30 μM from 50 μM (P<0.0005).
We also noticed that the onset of the oscillations, after synchronization, was dose-dependently
delayed by SP600125 treatment (Fig. 4C). We defined the onset of the oscillations as the time
at which the bioluminescence level reached its first trough after medium change. As compared
with the control condition, where the onset was at 17.98±0.53 h, 3 μM SP600125 did not delay
the onset (17.83±0.20 h, P>0.1). On the contrary, 10 μM (20.94±0.36 h, P<0.05), 30 μM (23.80
±0.94 h, P<0.0005), and 50 μM inhibitor (29.06±0.61 h, P<0.0005) significantly delayed the
onset. The delay observed was also significantly higher after 10 μM treatment than 3 μM
treatment (P<0.0005). Similarly, 30 μM SP600125 treatment delayed the onset of the
oscillations more than 10 μM SP600125 treatment (P<0.05), and 50 μM more than 30 μM
(P<0.005).
The effects of SP600125 on the period length in various tissues
The effects of 30 μM SP600125 were further evaluated in diverse tissues. In the SCN, the
period of the bioluminescence rhythm was significantly extended in Period1-luciferase
transgenic mice (P<0.005; Table 1, Fig. 5A) and Period2Luciferase SCN slices (P<0.05, Table
1, Fig. 5A).
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We then studied the effects of SP600125 on the pineal gland, lungs and kidneys. First, in the
pineal gland of Period1-luciferase mice, the period was significantly extended (P<0.005, Table
1, Fig. 5B). Similar results were obtained with the Period2Luciferase pineal gland (P<0.0005,
Table 1, Fig. 5B). In lungs obtained from Period1-luciferase mice, the period length was
significantly increased with the SP600125 treatment (P<0.05, Table 1, Fig. 6A). In
Period2Luciferase mice, the period was significantly lengthened as well (P<0.0005, Table 1,
Fig. 6A).
In the SCNs, pineal glands and lungs obtained from Period1-luciferase and Period2Luciferase
mice, amplitudes and damping rates were not affected by SP600125 treatment (P>0.1, Table
1, Figs. 5A, B and 6A).
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However, oscillations in kidneys observed in the presence of SP600125 showed more
compound results (Table 1, Fig. 6B). When analyzing the entire 7 day sample, none of the
SP600125-treated Period1-luciferase samples showed significant circadian oscillation
(P>0.05), whereas seven of nine Period2Luciferase samples did show significant circadian
oscillations in the presence of SP600125 (P<0.05). Interestingly, the Period2Luciferase samples
showed oscillations that were much stronger for the first 2 days in cultures, strongly damping
subsequently, and 7 of 16 Period1-luciferase samples showed some evidence for circadian
oscillations on the first 2 days of culture. The rhythmic Period2Luciferase cultures did not show
a circadian period significantly different from that of controls (P>0.05, Table 1, Fig. 6B). So
were the amplitude and damping rate (P>0.05, Table 1).
The effects of valproic acid on JNK phosphorylation levels and the period of circadian
oscillations
We treated rat-1 Period1-luciferase fibroblasts with 1 mM valproic acid since it has been shown
to affect the period length of locomotor behavior in Drosophila and mammals. We found that
the period of the bioluminescence oscillations was significantly shortened as compared with
the control condition (P<0.05; Table 1, Fig. 7A). Although the amplitude of the oscillations
was significantly increased by the treatment (P<0.05, Table 1), the damping rate remained
unchanged (P>0.1, Table 1). Both p46 kDa and p54 kDa JNK isoforms showed hyper-
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phosphorylation after 12 h of valproic acid treatment (both cases, P<0.005, Fig. 7B). For
comparison, when cells were treated with 30 μM SP600125 for 12 h, p46 kDa and p54 kDa
phosphorylation levels were not significantly different from control groups (P>0.05 and P>0.1
respectively), but they were significantly lower than those in the valproic acid-treated groups
(both cases, P<0.0005; Fig. 7B). Total levels of p46 kDa and p54 kDa were not affected by
any treatments (in all the cases, P>0.1).

DISCUSSION
Our studies demonstrate an important role of JNK activation in the regulation of circadian
rhythms. We found that p46 kDa and p54 kDa JNK isoforms were both acutely phosphorylated
after synchronization of rat-1 fibroblasts and that p46 kDa phosphorylation level was rhythmic
over the circadian cycle (Fig. 1, 3). The JNK inhibitor SP600125 dramatically lengthened the
period of reporter gene expression in a dose-dependent fashion (Fig. 2, 4B). This effect was
found in the SCN and some peripheral oscillators of both Period1-luciferase transgenic mice
and Period2Luciferase knockin mice (Fig. 5, 6). In contrast, we demonstrated that increasing
phosphorylated forms of JNK with valproic acid shortened the circadian period (Fig. 7).
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Ten JNK isoforms of either 46 kDa or 54 kDa have been identified (Derijard et al., 1994; Gupta
et al., 1996). These are coded from three genes (Jnk1, Jnk2, Jnk3) through alternative splicing.
Jnk3 gene expression is restricted to the CNS, and to a lesser extent to the heart and testis.
Therefore, p46 kDa and p54 kDa isoforms, found in the present study, represent JNK1 and
JNK2 in fibroblasts (Figs. 1, 3, 7). Although p46 kDa and p54 kDa isoforms are both acutely
phosphorylated upon medium change, only p46 kDa isoforms display a rhythmic
phosphorylation profile over the next 24 h. (Fig. 1). This finding suggests that JNK isoforms
may mediate distinct signals and information in these cells. Support for the latter idea comes
from the study of JNK isoforms roles in other systems and the finding that JNK1 and JNK2
isoforms activation can drive opposite responses, as it has been demonstrated for c-JUNdependent cell proliferation (Sabapathy et al., 2004). The JNK phosphorylation that we report
here is consistent with a previous study in which JNK show circadian activation in the SCN
of Syrian hamster, in vivo (Pizzio et al., 2003). The related p38MAPK and ERK subfamilies
activation were found rhythmic in tissues containing circadian oscillators. First, p38MAPK
phosphorylation levels oscillate in the rat and chick pineal gland where these kinases have been
shown to control the period and phase of circadian rhythms (Hayashi et al., 2003; Hasegawa
and Cahill, 2004). Second, daily and circadian rhythms of ERK activations occur respectively
in the rat pineal gland (Ho et al., 2003), and in both Syrian hamster and mouse SCN (Obrietan
et al., 1998; Pizzio et al., 2003). In the mouse SCN, ERK is known to participate to the
entrainment of rhythms by light cycles (Butcher et al., 2002; Dziema et al., 2003). These data
allowed us to raise the hypothesis that JNK might play a role in the circadian machinery.
To determine the role of JNK phosphorylation in circadian rhythm regulation, we utilized an
inhibitor of JNK activation, SP600125. This potent and selective ATP-competitive inhibitor
is effective on all isoforms of JNK and exhibits over 300-fold greater selectivity for JNK as
compared with related kinases of the ERK and p38MAPK families (Bennett et al., 2001).
SP600125 is described as a reversible and dose-dependent inhibitor (Bennett et al., 2001).
Using the real-time bioluminescence monitoring system to record Period1-driven
bioluminescence rhythms, we notably found that SP600125 dose-dependently lengthens the
period of the oscillations in a reversible manner, and delays the onset of the oscillations (Fig.
4). This effect was intriguing by its magnitude, although a similar phenomenon but with a
lesser degree, has been described by Hayashi et al. (2003). Following inhibition of p38MAPK
activation, using its inhibitor SB203580, Hayashi et al. (2003) found the free-running period
of the rhythm of melatonin release in cultured chick pineal cells extended from 24.0±0.3 h to
28.7±1.1 h. They also reported that a 4 h-pulse of SB203580 given during the subjective day
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could delay the phase of the melatonin release rhythm. SP600125 could also dose-dependently
delay the phase of the rhythm of melatonin release from Xenopus photoreceptor layers
(Hasegawa and Cahill, 2004). The similar effects of SB203580 and SP600125 might suggest
that p38MAPK and JNK are both involved in the regulation of the circadian molecular
clockwork. Moreover, Hasegawa and Cahill (2004) suggested that SB203580 not only inhibits
activation of p38MAPK but also other kinases, including JNK1, JNK2 and JNK3. This finding
implies that the effects of SB203580 on lengthening the period, as well as delaying the phase,
reported by Hayashi et al. (2003), might actually be an effect of both p38MAPK and JNK
inhibitions.
In the SCN from Period1-luciferase transgenic mice and Period2Luciferase knockin mice, we
observed a comparable SP600125-induced lengthening of the period (Table 1, Fig. 5A).
Likewise, an extra-SCN brain region (pineal gland) and a peripheral tissue (lung) known to
contain circadian clocks (Sakamoto et al., 1998;Yamazaki et al., 2002;Karolczak et al.,
2004;Simonneaux et al., 2004;Fukuhara et al., 2005) demonstrated an analogous effect of
SP600125 (Table 1, Figs. 5B and 6A). It is noteworthy that in the SCN and the pineal gland,
in which the three Jnk genes are expressed, we cannot exclude a putative involvement of JNK3
isoforms in the modulation of the period by SP600125 treatment.
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Interestingly, kidneys that rhythmically express circadian clock genes (Sakamoto et al.,
1998; Yamazaki et al., 2002; Yoo et al., 2004) are affected by SP600125 treatment in a different
fashion than other tissues (Fig. 6B). The discrepancy between results of Period1-luciferase
and Period2Luciferase could be explained by the different DNA constructs used to produce
transgenic and knockin animals. Indeed, the Period2Luciferase mice have been produced by
insertion of the luciferase reporter gene after the Period2 endogenous coding sequence (Yoo
et al., 2004) and thus are likely to drive more stable oscillations than the Period1-luciferase
transgenic mice (Yamazaki et al., 2000; Herzog et al., 2004). Alternative explanations will be
either a higher sensitivity of kidney tissue to the inhibitor, or an organ-specific effect of
SP600125 on regulation of circadian oscillations. To test the first hypothesis, we assayed the
Period1-bioluminescence rhythms in the presence of 15 μM SP600125, but found similar
rhythm disruption as seen with the 30 μM-treatment (data not shown). It is therefore likely that
the effects of SP600125 on circadian oscillations are tissue-specific.
What might be the mechanisms of the action of SP600125 in the modulation of the period
length? First, it is noticeable that the effects of SP600125 are not due to toxicity, because we
demonstrated that after 3 days of SP600125 treatment, when the clock is already slowed down
due to the inhibitor, the cell survival rate is identical in the SP600125-treated and non-treated
samples.
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It is most likely that SP600125 lengthens period through changes in JNK phosphorylation
levels. First, we show that the lengthening effect of SP600125 in fibroblasts is associated with
both a complete inhibition of the acute phosphorylation of p46 kDa and p54 kDa isoforms,
confirming that SP600125 efficiently worked in our model, and an abolishment of the rhythmic
phosphorylation of p46 kDa isoforms (Fig. 3). Contrary to p46 kDa whose baseline
phosphorylation levels were reduced during the 24 h of SP600125 treatment, p54 kDa
phosphorylation levels remained unchanged as compared with the control condition (Fig. 1,
3B). This finding suggests that the p54 kDa phosphorylation levels detected in the control
condition correspond to the baseline levels and that p54 kDa is likely to be acutely but only
transiently phosphorylated, as opposed to p46 kDa. We also show that valproic acid both
increases activation of both isoforms of JNK (Fig. 7B), and shortens the period of
bioluminescence oscillations in fibroblasts (Fig. 7A). Current literature on the effect of valproic
acid on circadian rhythms is not consistent, though. Valproic acid has been shown to lengthen
the period of free-running locomotor activity rhythms and increase arrhythmicity in
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Drosophila housed in constant darkness (Dokucu et al., 2005), but it does not seem to alter any
rhythmic parameters in Syrian hamster maintained in constant darkness (Klemfuss and Kripke,
1995). Another group showed that valproic acid increases activity duration of rats while
shortening the period length of their free-running circadian rhythmicity (Rietveld and van
Schravendijk, 1987). To provide firm evidence that valproic acid is affecting the mammalian
circadian clock, we treated Period1-luciferase SCN slices using 1 mM valproic acid, and found
that the period was shortened (22.60 h, data not shown). Although we suggest here that valproic
acid may regulate the period length through an effect on JNK, it should be noted that the related
kinase ERK is also activated by valproic acid (Yuan et al., 2001). We thus cannot exclude the
possibility that valproic acid utilizes multiple pathways to mediate period shortening. Taken
together, these results suggest that JNK phosphorylation levels may participate in the regulation
of circadian rhythms’ period length. As bipolar disorder patients experience unstable circadian
rhythms, and treating patients with valproic acid remarkably stabilizes their mood (Goodwin
and Jamison, 1990;Tsujimoto et al., 1990;Jones et al., 2005), it would be interesting to further
investigate whether the effect of SP600125 on period and perhaps other circadian parameters
is related to mood stabilizing effect.
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A possible mechanism for the action of JNK might be alteration of the activity levels of some
of the downstream targets of the JNK. As it has been demonstrated that ERK1/2 interacts with
and phosphorylates BMAL1 (Sanada et al., 2002) and CRY1/2 (Sanada et al., 2004) proteins
to control their stability, a similar function of JNK is conceivable. Alternatively, JNKs are
potent activators of c-JUN, which participates in the formation of the activator protein-1 (AP-1)
transcription activator complex. AP-1 is known to regulate gene expression through binding
to the tetradecanoyl phorbol acetate response element (TRE, consensus sequence 5’-TGAG/
CTCA-3’) binding site located in the promoter of numerous genes (Hess et al., 2004).
Therefore, changing JNK activation levels by treating with SP600125 or valproic acid might
affect the transcription of circadian clock genes through an AP-1 regulation. Period1 promoters
of mouse and rat genes, including the 6.7 kb used to create the Period1-luciferase DNA
construct for Period1-luciferase mice (Herzog et al., 2004), seem to contain four AP-1mediated regulatory elements as described in a previous study (Chansard et al., 2005).
Likewise, we found two putative TRE binding sites in the mouse Period2 promoters that
localize at −1459 bp and −4470 bp (GenBank accession number NT_078297), from a
transcription start site located at 6063573 bp. Taken together, it strengthens the possibility that
the periods of the bioluminescence rhythms might be modulated through an AP-1 activity.
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Although SP600125 has been described as a highly specific inhibitor for JNK activation
(Bennett et al., 2001), other kinases may also be affected by this drug (Bain et al., 2003). For
example, the activity of cyclin-dependent kinase 2 (CDK-2), which controls the cell cycle, is
inhibited by SP600125 (Malumbres and Barbacid, 2005). Previous reports showed that
olomoucine, an inhibitor of this kinase (CDK-2), dose-dependently lengthens the period in the
eye of the marine snail Bulla gouldiana (Krucher et al., 1997), and phase-delays the rhythm
of Aplysia ocular circadian rhythm (Sankrithi and Eskin, 1999). Despite a lower magnitude of
the period lengthening effect, those effects on the circadian oscillations are similar to what we
report here using SP600125; thus, we cannot exclude the possibility that both JNK and CDK-2
inhibitions are responsible for the period lengthening. Additional investigations will be
necessary to understand the participation of other kinases in the modulation of period length
by SP600125.
Over the past few years, protein kinases have been proven to play a critical role in the regulation
of circadian rhythm generation. However, the real importance of this post-translational
modification in the mechanisms of circadian clocks remains unclear. Data collected in several
organisms have shown that the phosphorylation status of some of the circadian clock proteins
affects their stability and their participation in the regulation of the core transcriptional loops
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of circadian clocks. For example, circadian period in Drosophila, is controlled by casein kinase
II (Akten et al., 2003) and DOUBLETIME (Price et al., 1998; Bao et al., 2001) which
destabilize, and PROTEIN PHOSPHATASE 2A, which stabilizes, the core loop component,
PERIOD protein (Sathyanarayanan et al., 2004). This tight regulation of PERIOD
phosphorylation eventually determines the timing of the PERIOD- and TIMELESS-driven
inhibition of Period and Timeless transcription through an action on the CLOCK-CYCLE
heterodimer. Some data collected in several organisms suggest that phosphorylation of clock
proteins might even play a greater role than initially suspected. The most striking of these data
have come from a study performed by Nakajima and colleagues (2005) on the cyanobacteria
circadian clock. In this study, the three main components of the cyanobacteria circadian
machinery, the KaiA, KaiB and KaiC proteins, were incubated in vitro in the presence of ATP.
In these conditions and thus in the absence of any transcription, the KaiC phosphorylation
robustly oscillated with a period of about 24 h and this phenomenon was temperaturecompensated, a characteristic of circadian rhythms (Nakajima et al., 2005). This astonishing
result raises questions about the nature of the role of both transcription and translation into the
molecular mechanisms of circadian clocks. The magnitude of the effect we observed when
changing JNK phosphorylation levels with SP600125 supports the idea of a major role for
clock protein phosphorylation by JNK in the mechanisms of circadian clocks. Additional
studies will allow us to understand the mechanism of JNK-specific period regulation.
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mitogen-activated protein kinases
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TRE
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Fig. 1. Phosphorylation of JNK isoforms in synchronized rat-1 fibroblasts
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Twenty-four hours after synchronization, cells were harvested at 4-h intervals on a circadian
cycle. (A) Phosphorylation of p46 kDa isoforms showed a rhythmic pattern (open square,
P<0.05) over the circadian cycle with a peak of phosphorylation reached 44 h after
synchronization. Total amount of p46 kDa was unchanged (filled circle, P>0.1). (B) p54 kDa
isoform phosphorylation (open square) as well as total protein amounts (filled circle) did not
show significant variations (both cases, P>0.1). Period1-luciferase rhythmic bioluminescence
expression on the same time window is represented (A and B). Values are means±S.E.M.
n=4–5 For each time point. *P<0.05. For symbols without standard error bars, the bars are
smaller than the size of symbols.
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Fig. 2. The effects of SP600125 on the period of Period1-luciferase bioluminescence rhythms in rat-1
fibroblasts
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Fibroblasts were synchronized by medium change and Period1-driven bioluminescence was
recorded for several days. SP600125 (30 μM) lengthened the period of the bioluminescence
rhythms. SP600125 negative control (30 μM) showed no significant effect. The left panels
show the representative raw bioluminescence recordings and the right panels the baselinecorrected bioluminescence data. The columns in the lower panel show the estimated period
length in each experimental condition. Values are means±S.E.M. *** P<0.005; ns, not
significant. In all figures a number shown in a column indicates sample size.
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Fig. 3. The effects of SP600125 on the acute and chronic activation of JNK in rat-1 fibroblasts

(A) Fibroblasts were synchronized by medium change with or without SP600125. The acute
phosphorylation of p46 kDa and p54 kDa isoforms, measured 20 min after medium change
was inhibited by SP600125. The lower panel shows quantitative data. Control (0 min) levels
were normalized as 100. See detailed description in Fig. 1. (B) Cells were harvested on a full
circadian cycle at 5-h intervals starting 30 h after medium change. p46 kDa and p54 kDa
isoforms (open square), normalized toward the respective peak time level of expression in the
control condition (shown in Fig. 1), did not show significant rhythmicity (both cases, P>0.01).
Total amounts of both isoforms remained unvaried (both cases, P>0.1). Values are means
±S.E.M. n=3 For each time point. Period1-luciferase rhythmic expression on the same time
window is represented. * P<0.05; ** P<0.005; *** P<0.0005.
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Fig. 4. Characteristics of SP600125 in the regulation of the Period1-driven bioluminescence rhythm
in rat-1 fibroblasts

(A) Circadian rhythmic expression of Period1-bioluminescence in fibroblasts were
synchronized and recorded for 3 days in the presence of 30 μM SP600125 (filled bar, 30.73
±0.16 h). Medium was then replaced by assay medium without SP600125. After washout, the
period was significantly shortened (24.44±0.10 h, P<0.0005). The graph is representative of
three independent experiments. n=7. (B) SP600125 showed dose-dependent effects on the
period lengthening. Data represent means±S.E.M. n=3–8 For each dose. Comparisons with
the control condition (“0”): * P<0.05; *** P<0.005. Comparisons among SP600125
conditions: a P<0.05; c P<0.005. (C) SP600125 dose-dependently delayed the time of the onset.
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Data shown represent means±S.E.M. Comparisons with the control condition: * P<0.05; ***
P<0.0005. Comparisons among SP600125 conditions: a P<0.05; b P<0.0005.
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Fig. 5. The effects of SP600125 treatment on the period of Period1- and Period2-driven
bioluminescence rhythms in SCN and pineal gland of transgenic/knockin mice

SCN slices from Period1-luciferase transgenic mice (left panels) and Period2Luciferase knockin
mice (right panels) showed a significant period lengthening in the presence of SP600125 (A).
A similar effect of SP600125 was found in the pineal gland (B). Bioluminescence values for
each corresponding daily time are plotted on the chart with time 0 as midnight (00:00 h) on
the starting day of the cultures. For each tissue, the left panel represents the raw
bioluminescence record and the right panel the baseline-corrected bioluminescence data. The
lower panel shows the estimated period length. Each graph is representative of three to four
independent experiments. Values are means±S.E.M. ** P<0.005; *** P<0.0005.
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Fig. 6. The effects of SP600125 treatment on the period of Period1- and Period2-driven
bioluminescence rhythms in peripheral tissues of transgenic/knockin mice
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Lung explants from Period1-luciferase transgenic mice (left panels) and Period2Luciferase
knockin mice (right panels) showed a significant period lengthening in the presence of
SP600125 (A). However, in the kidneys, circadian rhythms were abolished in Period1luciferase mice, while circadian rhythms were not affected by SP600125 treatment in
Period2Luciferase mice (B). Bioluminescence values for each corresponding daily time are
plotted on the chart with time 0 as midnight (00:00 h) on the starting day of the cultures. For
each tissue, the left panel represents the raw bioluminescence record and the right panel the
baseline-corrected bioluminescence data. The lower panel shows the estimated period length.
For Period1-luciferase kidneys, only control samples are shown because no significant
circadian rhythms or period was obtained in the presence of SP600125. Each graph is
representative of four to seven independent experiments. Values are means ±S.E.M. ns, Not
significant; * P<0.05; *** P<0.0005.
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Fig. 7. The effects of valproic acid treatment on the period of Period1-bioluminescence rhythms
and the phosphorylation level of JNK in rat-1 fibroblasts

(A) Rat-1 fibroblasts were synchronized and treated with 1 mM valproic acid. Period was
significantly shortened in the presence of valproic acid. Values are means±S.E.M. In each
graph, a number shown in a column indicates sample size. * P<0.05. Student’s t-test. (B) Rat-1
fibroblasts were cultured and treated for 12 h with either 30 μM SP600125 or 1 mM valproic
acid. SP600125 (SP) did not significantly affect the phosphorylation levels of p46 kDa and
p54 kDa, while valproic acid (VA) hyper-phosphorylated both isoforms. Total JNK levels were
not affected by SP or VA treatment. Values are means±S.E.M. n=3–4 For each treatment. **
P<0.005; *** P<0.0005; ns, not significant.
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Table 1

NIH-PA Author Manuscript
lungs

kidneys

32.83 ± 1.04**
23.87 ± 0.13
35.35 ± 0.93***
24.63 ± 0.27
30.56 ± 1.45*
23.65 ± 0.12
32.78 ± 1.34***
24.54 ± 0.14
N/A
24.16 ± 0.20
25.46 ± 0.78 ns
23.98 ± 0.12
23.35 ± 0.17*

24.83 ± 0.38 ns
24.63 ± 0.59
32.45 ± 0.99**
24.10 ± 0.25
32.96 ± 1.19*
23.55 ± 0.25

24.23 ± 0.17
24.28 ± 0.20 ns
31.48 ± 0.07***

Period (h)

p<0.0005.

p<0.005.

***

**

p<0.05.

*

N/A, analysis not possible due to a lack of rhythmicity; ns, not significant; SP, SP600126.

Period1-luciferase rat-1 fibroblasts

Mouse Period2

Luciferase

Mouse Period1-luciferase kidneys

Mouse Period2

Luciferase

Mouse Period1-luciferase lungs

Mouse Period2Luciferase pineal gland

Mouse Period1-luciferase pineal
gland

Mouse Period2Luciferase SCN

SP600125 30μM
Control
SP600125 30μM
Control
SP600125 30μM
Control
SP600125 30μM
Control
SP600125 30μM
Control
SP600125 30μM
Control
Valproic acid 1mM

Control
DMSO
SP600125 30μM
SP, negative control 30μM
Control
SP600125 30μM
Control
SP600125 30μM
Control

Period1-luciferase rat-1 fibroblasts

Mouse Period1-luciferase SCN

Treatment

Cell type/tissue

330.23 ± 138.32 ns
79.56 ± 20.47
87.22 ± 19.68 ns
175.35 ± 48.60
151.03 ± 68.12 ns
33.29 ± 19.64
63.44 ± 23.26 ns
15.52 ± 4.42
N/A
258.96 ± 201.11
21.78 ± 10.92 ns
141.60 ± 19.99
503.25 ± 119.58*

188.11 ± 21.20
285.06 ± 12.52*
260.27 ± 50.62 ns
181.85 ± 21.47 ns
234.81 ± 84.02
197.75 ± 119.46 ns
150.74 ± 55.86
75.35 ± 10.11 ns
44.51 ± 12.59

Amplitude (counts/s)

1.01 ± 0.03 ns
1.70 ± 0.33
1.73 ± 0.09 ns
1.88 ± 0.17
2.80 ± 0.86 ns
3.29 ± 0.55
1.92 ± 0.16 ns
3.97 ± 0.53
N/A
1.34 ± 0.25
1.40 ± 0.15 ns
1.70 ± 0.14
1.59 ± 0.44 ns

1.72 ± 0.23
1.57 ± 0.09 ns
1.30 ± 0.05 ns
2.06 ± 0.35 ns
1.22 ± 0.25
1.05 ± 0.23 ns
4.12 ± 1.16
2.93 ± 0.48 ns
2.60 ± 0.57

Damping rate (d)

NIH-PA Author Manuscript

Period, amplitude and damping rate analyses of bioluminescence patterns following various treatments

Fig. 7A

Fig. 6B

Fig. 6B

Fig. 6A

Fig. 6A

Fig. 5B

Fig. 5B

Fig. 5A

Fig. 5A
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